GetTopicDetailResponse(id=7806111e2630, topicName=鉑耐藥卵巢癌, introduction=鉑耐藥卵巢癌, content=西地尼布 奧拉帕利 鉑耐藥卵巢癌, image=null, comments=0, allHits=889, url=null, type=0, isShow=1, status=1, isAdmin=null, adminId=5395722, adminEncryptionId=cade5395722, adminName=梅斯管理員, createdBy=cade5395722, createdName=梅斯管理員, createdAvatar=, createdTime=Thu Feb 29 16:55:03 CST 2024, time=2024-02-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=114961, tagList=[TagDto(tagId=114961, tagName=鉑耐藥卵巢癌)], ipAttribution=上海, topicAdmin=0, lengthMark=0)
[GetTopicListResponse(id=2260743, encodeId=48d32260e4370, content=<a href='/topic/show?id=aca3904e8a8' target=_blank style='color:#2F92EE;'>#西地尼布#</a> <a href='/topic/show?id=41f54454653' target=_blank style='color:#2F92EE;'>#奧拉帕利#</a> <a href='/topic/show?id=7b2910612398' target=_blank style='color:#2F92EE;'>#度伐利尤單抗#</a> <a href='/topic/show?id=7806111e2630' target=_blank style='color:#2F92EE;'>#鉑耐藥卵巢癌#</a>, objectTitle=CLIN CANCER RES | 比較度伐利尤單抗、奧拉帕利和西地尼布單藥治療、聯(lián)合治療或化療在鉑耐藥卵巢癌患者中的療效：NRG-GY023試驗, objectType=article, longId=872139, objectId=bb8a8e2139ab, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250415/1744719631745_6145188.jpg, objectUrl=/article/show_article.do?id=bb8a8e2139ab, replyNumber=0, likeNumber=36, createdTime=2025-04-16, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb8a8e2139ab, moduleTitle=CLIN CANCER RES | 比較度伐利尤單抗、奧拉帕利和西地尼布單藥治療、聯(lián)合治療或化療在鉑耐藥卵巢癌患者中的療效：NRG-GY023試驗, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=bb8a8e2139ab)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2190140, encodeId=a1372190140f6, content=<a href='/topic/show?id=aca3904e8a8' target=_blank style='color:#2F92EE;'>#西地尼布#</a> <a href='/topic/show?id=41f54454653' target=_blank style='color:#2F92EE;'>#奧拉帕利#</a> <a href='/topic/show?id=7806111e2630' target=_blank style='color:#2F92EE;'>#鉑耐藥卵巢癌#</a>, objectTitle=OCTOVA臨床試驗：奧拉帕利、化療或奧拉帕利聯(lián)合西地尼布在鉑耐藥卵巢癌患者中的隨機II期研究結(jié)果, objectType=article, longId=815176, objectId=d6758151e66f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240228/1709124756107_6145188.png, objectUrl=/article/show_article.do?id=d6758151e66f, replyNumber=0, likeNumber=111, createdTime=2024-02-29, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d6758151e66f, moduleTitle=OCTOVA臨床試驗：奧拉帕利、化療或奧拉帕利聯(lián)合西地尼布在鉑耐藥卵巢癌患者中的隨機II期研究結(jié)果, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=d6758151e66f)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯管理員
2024-02-29發(fā)表于上海
